2018 was definitely a year of innovation for the Pharma Industry. In the USA, the FDA approved a total of 61 drugs, exceeding its previous record of 50 approvals (in 1996), mostly for rare diseases, infectious diseases and cancer (check Forbes’ link for more information). In Europe, EMA recommended 84 medicines for marketing authorization, targeting mostly cancer, infections and neurologic disorders (access EMA’s report here).
At ELS Solutions, we strongly believe that we can contribute to reduce time to market in helping these products to be commercially available in LATAM and Europe. Using a state-of-the-art methodology for market access, regulatory prosecution and distribution hunting and management, ELS Solutions is equipped to be not only on the forefront of pragmatical innovation but specially to keep the pace of this new drug authorizations’ rhythm.
